Cell therapy · developed by Lisata Therapeutics
CLBS119 is an autologous cell preparation derived from peripheral blood CD34+ cells. It is studied in COVID-19 and related lung conditions including pneumonia and lung injury.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04522817 | Phase 1 | Covid-19 | Withdrawn | LSTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Covid-19
Updated Oct 25, 2026. Something wrong or missing? Report it on the LSTA page.
See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LSTA catalysts and pipeline →